IDX-184 is a superior HCV direct-acting antiviral drug: A QSAR study

Medicinal Chemistry Research

Volumn 25, Issue 5, 2016, Pages 1005-1008

  Elfiky, Abdo A ^a,b   Elshemey, Wael M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b LUND UNIVERSITY   (Sweden)

Author keywords

IDX 184; NS5B; Nucleotide inhibitors; QSAR; Sofosbuvir

Indexed keywords

CYTOSINE; GUANINE; IDX 184; MERICITABINE; RIBAVIRIN; SOFOSBUVIR; URACIL;

ARTICLE; DRUG APPROVAL; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HEPATITIS C VIRUS; PHASE 2 CLINICAL TRIAL (TOPIC); QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84960158342     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-016-1533-y     Document Type: Article

References (22)

1. Asselah T (2014) Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol 61:435-438
2. Beaulieu PL, Gillard J, Jolicoeur E, Duan J, Garneau M, Kukolj G, Poupart MA (2011) From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons. Bioorg Med Chem Lett 21:3658-3663
3. Choo AQ, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362
4. Das D, Hong J, Chen SH, Wang G, Beigelman L, Seiwert SD, Buckman BO (2011) Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorgan Med Chem 19:4690-4703
5. De Francesco R, Carfí A (2007) Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 59:1242-1262
6. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G (2003) Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antivir Res 58:1-16
7. Elfiky AA, Elshemey WM, Gawad WA, Desoky OS (2013) Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J 32(1):75-80
8. Elfiky AA, Elshemey WM, Gawad WA (2015) 2′-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in HCV inhibition: a Molecular Modeling study. J Comput Theor Nanosci 12:376-386
9. Elshemey WM, Elfiky AA, Gawad WA (2010) Correlation to protein conformation of wide-angle X-ray scattering parameters. Protein J 29:545-550
10. Firpi RJ, Nelson DR (2007) Current and future hepatitis C therapies. Arch Med Res 38:678-690
11. Gelman MA, Glenn JS (2010) Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med 17:34-46
12. Ibrahim M, Saleh NA, Elshemey WM, Elsayed AA (2012) Fullerene derivative as anti-HIV protease inhibitor: molecular modeling and QSAR approaches. Mini Rev Med Chem 12(6):447-451
13. Ibrahim M, Saleh NA, Elshemey WM, Elsayed AA (2013) QSAR properties of novel peptidomimetic NS3 protease inhibitors. J Comput Theor Nanosci 10(4):785-788
14. Klumpp K, Leveque V, Le Pogam S, Ma H, Jiang WR, Kang HS, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Najera I (2006) The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 281:3793-3799
15. Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA (2010) Development of novel therapies for hepatitis C. Antivir Res 86:79-92
16. Massariol MJ, Zhao S, Marquis M, Thibeault D, White PW (2010) Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. Biochem Biophys Res Commun 391:692-697
17. Mayhoub AS (2012) Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations. Biooran Med Chem 20:3150-3161
18. Mostafa HIA, El-Bialy NS, Ezat AA, Saleh NA, Ibrahim MA (2014) QSAR analysis and molecular docking simulation of suggested peptidomimetic NS3 protease inhibitors. Curr Comput Aided Drug Des 10(1):28-40
19. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HMM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA (2010) Mechanism of activation of PSI-7851 and its diastereoisomer Sofosbuvir. J Biol Chem 285:34337-34347
20. Saleh NA, Elfiky AA, Ezat AA, Elshemey WM, Ibrahim M (2014) The electronic and quantitative structure activity relationship properties of modified telaprevir compounds as HCV NS3 protease inhibitors. J Comput Theor Nanosci 11(2):544-548
21. Saleh NA, Ezat AA, Elfiky AA, Elshemey WM, Ibraheim M (2015) Theoretical study on modified boceprevir compounds as NS3 protease inhibitors. J Comput Theor Nanosci 12:371-375
22. Yang PL, Gao M, Lin K, Liu Q, Villareal VA (2011) Anti-HCV drugs in the pipeline. Curr Opin Virol 1:607-616